An Hsp90 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CUDC-305

Item No. 24683

Technical Information
Formal Name
4-amino-2-[[6-(dimethylamino)-1,3-benzodioxol-5-yl]thio]-N-(2,2-dimethylpropyl)-1H-imidazo[4,5-c]pyridine-1-ethanamine
CAS Number
1061318-81-7
Molecular Formula
C22H30N6O2S
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 10 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 5 mg/mlEthanol: 5 mg/ml
λmax
208, 291 nm
SMILES
CN(C)C(C=C(OCO1)C1=C2)=C2SC3=NC4=C(N)N=CC=C4N3CCNCC(C)(C)C
InChi Code
InChI=1S/C22H30N6O2S/c1-22(2,3)12-24-8-9-28-14-6-7-25-20(23)19(14)26-21(28)31-18-11-17-16(29-13-30-17)10-15(18)27(4)5/h6-7,10-11,24H,8-9,12-13H2,1-5H3,(H2,23,25)
InChi Key
RVJIQAYFTOPTKK-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    CUDC-305 is an orally bioavailable inhibitor of heat shock protein 90 (Hsp90; Item Nos. 22734 | 22735).1 It binds to Hsp90α and Hsp90β (IC50s = 100 and 103 nM for purified protein, respectively) as well as Hsp90 isolated from non-small cell lung cancer (NSCLC) cells resistant to erlotinib (Item No. 10483; IC50 = 70 nM).1,2 CUDC-305 induces degradation of Hsp90 client proteins in BT-474 breast cancer cells and inhibits proliferation of 40 human cancer cell lines (IC50s = 0.04-0.9 µM).1 It also reduces the levels of several oncoproteins including Akt and phosphorylated Akt, and ERK1/2 and phosphorylated ERK1/2 in a variety of cancer cell lines. CUDC-305 (40-160 mg/kg) dose-dependently reduces tumor growth in a U87MG glioblastoma mouse xenograft model and, when administered at a dose of 160 mg/kg, prolongs survival in a U87MG mouse orthotopic model.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bao, R., Lai, C.-J., Qu, H., et alCUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 15(12), 4046-4057 (2009).

    2. Bao, R., Lai, C.-J., Wang, D.-G., et alTargeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol. Cancer Ther. 8(12), 3296-3306 (2009).